INSCRIPTA® ACQUIRES INFINOME BIOSCIENCES AND SESTINA BIO TO ADVANCE SUSTAINABLE BIOMANUFACTURING
18 Jan 2023
Acquisition
PLEASANTON, Calif., Jan. 18, 2023 /PRNewswire/ -- Inscripta, a global leader in genome engineering technology, announced today the acquisition of two pioneers of synthetic biology – Infinome Biosciences and Sestina Bio, which advance Inscripta's strategy to develop and commercialize bio-manufactured products for a broad spectrum of industrial and consumer markets.
Continue Reading
The acquisitions demonstrate Inscripta's confidence in the commercial potential of the bioeconomy and the power of genome engineering to accelerate biomanufacturing innovation. "Tackling the unprecedented opportunity to improve global health and sustainability through biomanufacturing requires a strong combination of talent, experience, technology, and commercial assets," said Sri Kosaraju, CEO, Inscripta. "Infinome and Sestina Bio allow us to advance our strategy and complement our technological innovation and capabilities needed for creating the next generation of biobased manufacturing products and processes."
Inscripta is applying its cutting-edge technologies to biomanufacture products for industrial and consumer markets.
Tweet this
Prior to the acquisition, Infinome was closely affiliated with Inscripta. Infinome developed the GenoScaler™ platform, a proprietary strain engineering platform designed to rapidly optimize microbes for biomanufacturing, using Inscripta's genome engineering technology. "With our platform, we are able to create industrially optimized strains faster and at a fraction of the resource and infrastructure costs traditionally required for commercialization of precision fermentation solutions," said Infinome co-founder and CEO/CTO Dr. Richard Fox. "Combining Infinome with Inscripta brings together a shared vision of creating lean, scalable, and sustainable solutions for biomanufacturing through technology."
Sestina Bio brings an innovative, data-driven approach for building and identifying strains that make it out of the lab and withstand the rigors of commercial scale-up. "The proprietary methods we are developing enable us to produce and understand orders of magnitude more biological data than other synbio platforms," said Ted Tarasow, CTO, Sestina Bio. "Our approach to minimal strain design combined with Inscripta's unique genome editing capabilities will enable dramatic reductions in the time and cost of bringing products to market," added Andrew Horwitz, Vice President of R&D, Sestina Bio.
With the addition of Infinome and Sestina Bio, Inscripta is building on its history of technological innovation and has already begun applying its cutting-edge technologies to develop products for a diverse set of large industrial and consumer markets. Inscripta has several partnered and proprietary products in various stages of development. Kalsec® Inc., a food and beverage ingredient solutions company, represents one example of an announced partnership to develop and commercialize multiple bio-manufactured products. Separately, Inscripta is engaging in commercial conversations around the previously announced development of a ready-to-scale microbial strain producing Bakuchiol, a natural retinol replacement.
About Inscripta, Inc.
Inscripta® is a life science technology company committed to creating a cleaner, healthier, and more sustainable world through biomanufacturing. A global leader in genome engineering, our innovations are designed to unlock the full potential of the bioeconomy. We are committed to the continued development of critical technologies that enable scientists to bolster and expand domestic biomanufacturing, and spur new, safe, and secure biotech innovations. Inscripta supports customers around the world from facilities in Pleasanton and Burlingame, California.
To learn more, visit Inscripta.com or contact us directly at:
Michael B. Gonzales
Vice President, Marketing
[email protected]
415.308.6467
SOURCE Inscripta
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.